Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lifitegrast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 known ✓ | P05107 | 20/20 | 1.00 |
| ▸ | ITGAL known ✓ | P20701 | 20/20 | 1.00 |
| ▸ | ICAM1 | P05362 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lifitegrast SCHEMBL2632068 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL31010393 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL29386183 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL22556043 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL13167919 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL28561637 | 0.97 | ITGB2 (0.95) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL15445331 | 0.96 | ITGB2 (0.92) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL22929996 | 0.95 | ITGB2 (0.90) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL19134124 | 0.95 | ITGB2 (0.90) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL4756175 | 0.95 | ITGB2 (0.90) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1005 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137558-A1 | OPHTHALMIC DEVICE | Able Tx Ltd. (IL) | 2026-05-21 | — | — | US | claimed |
| EP-4739312-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS Therapeutics LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260078448-A1 | METHODS OF DETECTING SJÖGREN'S SYNDROME USING SALIVARY EXOSOMES | EXOSOME DIAGNOSTICS INC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260027050-A1 | ACOLTREMON COMBINATIONS AND USES THEREOF | ALCON INC (CH) | 2026-01-29 | — | — | US | claimed |
| US-20260021159-A1 | STABLE PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF MODERATE/SEVERE DRY EYE-RELATED OCULAR SYMPTOMS | TEARSOLUTIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-12492192-B2 | Crystalline form of lifitegrast, and pharmaceutical composition comprising the same | YS LIFE SCIENCE CO. LTD. (KR) | 2025-12-09 | — | — | US | claimed |
| WO-2025242919-A1 | NOVEL BINDING PROTEINS FOR HYALURONIC ACID | NAVIGO PROTEINS GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| WO-2025217189-A1 | EYEWEAR INCLUDING CHAMBER FOR OPTICAL SOLUTION | NATAR, LLC (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4584397-A1 | METHODS OF DETECTING SJÖGREN'S SYNDROME USING SALIVARY EXOSOMES | Exosome Diagnostics, Inc. (US) | 2025-07-16 | — | — | EP | claimed |
| US-20250221947-A1 | METHODS FOR TREATING A CORONAVIRUS INFECTION USING VALPROIC ACID AND DOCOSAHEXAENOIC ACID | UNIV TEXAS (US) | 2025-07-10 | — | — | US | claimed |
| US-11345683-B2 | Process for the preparation of lifitegrast | AUROBINDO PHARMA LTD (IN) | 2022-05-31 | — | — | US | claimed |
| CN-114555107-A | TSG6 polypeptide fragments for dry eye | 曼彻斯特大学 | 2022-05-27 | — | — | CN | claimed |
| WO-2022109497-A1 | FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE | SIGHT SCIENCES, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| WO-2022080887-A1 | CRYSTALLINE FORMS OF LIFITEGRAST, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 연성정밀화학(주) | 2022-04-21 | — | — | WO | claimed |
| WO-2022066891-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND AN ACTIVE AGENT | OCULAR THERAPEUTIX, INC. (US) | 2022-03-31 | — | — | WO | claimed |
| US-11286250-B2 | Process for preparing and purifying a LFA-1 antagonist | INTERQUIM, S.A. (ES) | 2022-03-29 | — | — | US | claimed |
| US-11273197-B2 | Adiponectin peptidomimetics for treating ocular disorders | ALLYSTA PHARMACEUTICALS, INC. (US) | 2022-03-15 | — | — | US | claimed |
| US-20220071945-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OCULAR SURFACE DISEASE | SURFACE OPHTHALMICS, INC. | 2022-03-10 | — | — | US | claimed |
| EP-3958889-A2 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | Sustain Holdings, LLC (US) | 2022-03-02 | — | — | EP | claimed |
| US-11246862-B2 | Process for the preparation of lifitegrast | MANKIND PHARMA LTD. (IN) | 2022-02-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492192-B2 | Crystalline form of lifitegrast, and pharmaceutical composition comprising the same | FGF23, FLT3, LPXN | ITGB2 971/4885ITGAL 1044/4885ICAM1 4484/4885 |
| US-11345683-B2 | Process for the preparation of lifitegrast | LIFR, IDUA, LMTK2 | ITGB2 1113/4885ITGAL 1125/4885ICAM1 4692/4885 |
| US-11246862-B2 | Process for the preparation of lifitegrast | LIFR, PTGFR, CSF1R | ITGB2 839/4885ITGAL 527/4885ICAM1 4016/4885 |
| US-20260078448-A1 | METHODS OF DETECTING SJÖGREN'S SYNDROME USING SALIVARY EXOSOMES | EXOSC10, EXOSC5, EXOSC9 | ITGB2 2567/4885ITGAL 1908/4885ICAM1 41/4885 |
| US-11286250-B2 | Process for preparing and purifying a LFA-1 antagonist | LIFR, ITGA1, ITGAL | ITGB2 13/4885ITGAL 3/4885ICAM1 75/4885 |
| US-20260021159-A1 | STABLE PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF MODERATE/SEVERE DRY EYE-RELATED OCULAR SYMPTOMS | TRPC1, TRPC7, ASNS | ITGB2 1868/4885ITGAL 688/4885ICAM1 1674/4885 |
| US-20260027050-A1 | ACOLTREMON COMBINATIONS AND USES THEREOF | TRPC7, TRPC5, TSLP | ITGB2 2598/4885ITGAL 734/4885ICAM1 2044/4885 |
| US-20220071945-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OCULAR SURFACE DISEASE | EYA3, HSD3B1, HMGCR | ITGB2 511/4885ITGAL 600/4885ICAM1 1231/4885 |
| US-20260137558-A1 | OPHTHALMIC DEVICE | IL2, ICOS, TRHDE | ITGB2 205/4885ITGAL 632/4885ICAM1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.